Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia With FLT3/ITD Mutation: early-phase trial registry
2 of 3 indexed Acute Myeloid Leukemia With FLT3/ITD Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia With FLT3/ITD Mutation: 3 US clinical trials tracked, 2 recruiting.
Acute Myeloid Leukemia With FLT3/ITD Mutation is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Uma Borate, running 1 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia-with-flt3itd-mutation
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Acute Myeloid Leukemia With FLT3/ITD Mutation lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia With FLT3/ITD Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia With FLT3/ITD Mutation is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Uma Borate
NCT06222580
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
H. Lee Moffitt Cancer Center and Research Institute
NCT05024552
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01253070
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia With FLT3/ITD Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia With FLT3/ITD Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia With FLT3/ITD Mutation page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Acute Myeloid Leukemia With FLT3/ITD Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Uma Borate sponsors the most Acute Myeloid Leukemia With FLT3/ITD Mutation trials on record, review their full trial history before evaluating a specific study. See Uma Borate's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia With FLT3/ITD Mutation condition card totals 3 registered trials; most-linked intervention Gilteritinib; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.